Blab Business
Quanterix Eyes Cash-Flow Breakeven in 2026 After Akoya Acquisition and Management Overhaul
On July 8 2025, Quanterix Corporation (NASDAQ: QTRX) announced the completion of its purchase of Akoya Biosciences, a move that has already begun reshaping the company’s trajectory. With a fresh leadership slate and a clear focus on commercial execution, Quanterix now targets cash‑flow breakeven in the second half of 2026.
The Akoya deal, first revealed in January 2025, delivers the industry’s first fully integrated platform that measures protein biomarkers in both blood and tissue. The company’s press release highlights how the acquisition expands Quanterix’s spatial biology capabilities and brings a new customer base that could accelerate revenue growth. By marrying Akoya’s spatial imaging with Quanterix’s ultra‑sensitive Simoa (Single Molecule Array) technology, the combined entity is poised to offer a broader portfolio and generate significant cost synergies.
Management changes followed swiftly. Masoud Toloue was installed as president and CEO, while Jason Faessler assumed the role of chief financial officer on June 22 2026. Anthony Catalano joined as chief operating officer on May 14 2026, and the company announced the departure of former CFO Vandana Sriram on June 15 2026. Senior directors Aaron Llanso and Mingwei Zhao were also added to the leadership team, rounding out a group known for turning around microcap companies.
In its first earnings report after the acquisition, Quanterix reported a 20 % year‑over‑year revenue increase in Q1 2026. The company noted improved adjusted margins and a strong cash position, while re‑classifying shipping costs into cost of revenue. Analysts observed that the firm remains on a path toward cash‑flow breakeven, with guidance that the milestone will be achieved by the fourth quarter of 2026.
Quanterix’s flagship product, the LucentAD blood test, is a multi‑analyte algorithm that assists clinicians in evaluating patients with cognitive symptoms for potential Alzheimer’s disease. The company submitted a 510(k) pre‑market notification to the U.S. Food and Drug Administration in 2025. Leveraging the Simoa platform, the test offers ultra‑sensitive protein detection that can identify hidden cases in large population studies, such as the Norwegian Trøndelag Health trial.
International interest has followed the Alzheimer’s test. In 2025, a Korean company secured an exclusive agreement to introduce the Simoa platform and related reagents for Alzheimer’s screening in Korea, underscoring the test’s clinical relevance.
Despite these advances, execution and adoption risks linger. Integrating Akoya’s spatial biology platform requires converting new technology into revenue without incurring further goodwill write‑downs. Analysts have cautioned that the cash‑flow breakeven target is ambitious, given the capital intensity of Quanterix’s research and development pipeline.
The new management team’s track record in microcap turnarounds is central to the company’s optimism. Industry data suggest that a focus on cost synergies and commercial execution has already begun to tilt Quanterix’s financial trajectory from persistent losses toward a path of profitability.
Quanterix’s installed base of laboratories and clinical partners provides a foundation for recurring revenue. The company plans to leverage this base to accelerate adoption of its biomarker platform across neurology, oncology, and other therapeutic areas.
The next public disclosure will be the Q2 2026 earnings report, a key barometer for investors. Market watchers will look for continued revenue growth, margin improvement, and evidence of progress toward the cash‑flow breakeven milestone. Regulatory developments—particularly FDA clearance of the LucentAD test—and the performance of the integrated Akoya platform will also shape the company’s trajectory.
In short, Quanterix’s acquisition of Akoya Biosciences, coupled with a new management team and a clear focus on cost synergies, positions the company to move from a history of losses to a projected cash‑flow breakeven in 2026. Its biomarker technology, especially the Alzheimer’s blood test, offers significant growth potential, but execution and market adoption remain critical to realizing that promise.
The Akoya deal, first revealed in January 2025, delivers the industry’s first fully integrated platform that measures protein biomarkers in both blood and tissue. The company’s press release highlights how the acquisition expands Quanterix’s spatial biology capabilities and brings a new customer base that could accelerate revenue growth. By marrying Akoya’s spatial imaging with Quanterix’s ultra‑sensitive Simoa (Single Molecule Array) technology, the combined entity is poised to offer a broader portfolio and generate significant cost synergies.
Management changes followed swiftly. Masoud Toloue was installed as president and CEO, while Jason Faessler assumed the role of chief financial officer on June 22 2026. Anthony Catalano joined as chief operating officer on May 14 2026, and the company announced the departure of former CFO Vandana Sriram on June 15 2026. Senior directors Aaron Llanso and Mingwei Zhao were also added to the leadership team, rounding out a group known for turning around microcap companies.
In its first earnings report after the acquisition, Quanterix reported a 20 % year‑over‑year revenue increase in Q1 2026. The company noted improved adjusted margins and a strong cash position, while re‑classifying shipping costs into cost of revenue. Analysts observed that the firm remains on a path toward cash‑flow breakeven, with guidance that the milestone will be achieved by the fourth quarter of 2026.
Quanterix’s flagship product, the LucentAD blood test, is a multi‑analyte algorithm that assists clinicians in evaluating patients with cognitive symptoms for potential Alzheimer’s disease. The company submitted a 510(k) pre‑market notification to the U.S. Food and Drug Administration in 2025. Leveraging the Simoa platform, the test offers ultra‑sensitive protein detection that can identify hidden cases in large population studies, such as the Norwegian Trøndelag Health trial.
International interest has followed the Alzheimer’s test. In 2025, a Korean company secured an exclusive agreement to introduce the Simoa platform and related reagents for Alzheimer’s screening in Korea, underscoring the test’s clinical relevance.
Despite these advances, execution and adoption risks linger. Integrating Akoya’s spatial biology platform requires converting new technology into revenue without incurring further goodwill write‑downs. Analysts have cautioned that the cash‑flow breakeven target is ambitious, given the capital intensity of Quanterix’s research and development pipeline.
The new management team’s track record in microcap turnarounds is central to the company’s optimism. Industry data suggest that a focus on cost synergies and commercial execution has already begun to tilt Quanterix’s financial trajectory from persistent losses toward a path of profitability.
Quanterix’s installed base of laboratories and clinical partners provides a foundation for recurring revenue. The company plans to leverage this base to accelerate adoption of its biomarker platform across neurology, oncology, and other therapeutic areas.
The next public disclosure will be the Q2 2026 earnings report, a key barometer for investors. Market watchers will look for continued revenue growth, margin improvement, and evidence of progress toward the cash‑flow breakeven milestone. Regulatory developments—particularly FDA clearance of the LucentAD test—and the performance of the integrated Akoya platform will also shape the company’s trajectory.
In short, Quanterix’s acquisition of Akoya Biosciences, coupled with a new management team and a clear focus on cost synergies, positions the company to move from a history of losses to a projected cash‑flow breakeven in 2026. Its biomarker technology, especially the Alzheimer’s blood test, offers significant growth potential, but execution and market adoption remain critical to realizing that promise.
